EyePoint Pharmaceuticals (EYPT) Equity Average: 2011-2019
Historic Equity Average for EyePoint Pharmaceuticals (EYPT) over the last 7 years, with Mar 2019 value amounting to $28.8 million.
- EyePoint Pharmaceuticals' Equity Average rose 217.68% to $28.8 million in Q1 2019 from the same period last year, while for Mar 2019 it was $28.8 million, marking a year-over-year increase of 217.68%. This contributed to the annual value of $12.5 million for FY2018, which is 26.87% down from last year.
- Per EyePoint Pharmaceuticals' latest filing, its Equity Average stood at $28.8 million for Q1 2019, which was down 32.61% from $42.7 million recorded in Q4 2018.
- Over the past 5 years, EyePoint Pharmaceuticals' Equity Average peaked at $42.7 million during Q4 2018, and registered a low of $9.1 million during Q1 2018.
- Moreover, its 3-year median value for Equity Average was $12.9 million (2017), whereas its average is $18.6 million.
- As far as peak fluctuations go, EyePoint Pharmaceuticals' Equity Average crashed by 51.16% in 2015, and later surged by 351.38% in 2018.
- Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' Equity Average stood at $16.6 million in 2015, then dropped by 12.51% to $14.5 million in 2016, then tumbled by 35.00% to $9.5 million in 2017, then skyrocketed by 351.38% to $42.7 million in 2018, then surged by 217.68% to $28.8 million in 2019.
- Its Equity Average was $28.8 million in Q1 2019, compared to $42.7 million in Q4 2018 and $29.7 million in Q3 2018.